What we do
Access program
In collaboration with the World Health Organization (WHO) and external experts, the Consortium developed an Access & Delivery strategy that will ensure accessibility and affordability of the new treatment based on an innovative not-for-profit procurement mechanism.
Access and affordability path
- Now approved, the product is being made available on a not-for-profit basis. Together with external stakeholders, the Consortium has explored not-for-profit procurement models and innovative financing mechanisms to ensure sustainable access to countries.
- To ensure affordability of the product, an equitable pricing strategy was built into the program from the beginning. All Research & Development investments from partners and funders are delinked from the final cost of the product. Stringent manufacturing methods and processes were taken to decrease the Cost of Goods (CoGs) to the minimum.
- To allow for large-scale production of the new product and address the needs of endemic countries in Africa, a partnership with Universal in Kenya was signed and announced in 2021.
- Collaboration with the WHO Essential Medicines List team was secured and helped to ensure inclusion of the new treatment on the Essential Medicines List for Children. This will facilitate inclusion on National Essential Medicines Lists. Additionally, extensive conversations with various country institutions are ongoing to prepare and facilitate the path of inclusion of the new treatment in their local policy guidelines.